Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality

Critical Care Medicine

Volumn 29, Issue 3, 2001, Pages 473-481

  Remick, Daniel G ^a,b   Call, Douglas R ^a   Ebong, Samuel J ^a   Newcomb, David E ^a   Nybom, Pia ^a   Nemzek, Jean A ^a   Bolgos, Gerald E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b M2210 Medical Science Building I ^*  (United States)

Author keywords

Chemokines; Cytokines; Endotoxin shock; Immunomodulation; Infectious immunity bacteria; Inflammatory mediators; Multiple organ pathology; Rodent; Sepsis

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROGOL; MACROPHAGE INFLAMMATORY PROTEIN 2; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PERITONEAL FLUID; PERITONEUM CELL; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL;

EID: 0035100180     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200103000-00001     Document Type: Review

References (50)

1. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
2. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits
3. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial; TNF-α MAb Sepsis Study Group
4. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
5. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial; Ro 45-2081 Study Group
6. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: The Soluble TNF Receptor Sepsis Study Group
7. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial; Phase III rhIL-1ra Sepsis Syndrome Study Group
8. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial; The Interleukin-1 Receptor Antagonist Sepsis Investigator Group
9. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock
10. Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome: Why no magic bullets?
11. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function
12. Antibiotic treatment influences outcome in murine sepsis: Mediators of increased morbidity
13. Protective effects of C5a blockade in sepsis
14. Protection from septic shock by neutralization of macrophage migration inhibitory factor
15. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia
16. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture
17. Recombinant interleukin-1 receptor antagonist (IL-1ra): Effective therapy against gram-negative sepsis in rats
18. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor α required as a costimulatory factor for interferon γ-induced activation
19. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
20. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis
21. Sepsis and septic shock: A review of laboratory models and a proposal
22. Immunopathologic alterations in murine models of sepsis of increasing severity
23. Comparison of the mortality and inflammatory response of two models of sepsis: Lipopolysaccharide vs. cecal ligation and puncture
24. WEHI 164 subclone 13 assay for TNF: Sensitivity, specificity, and reliability
25. Production of hybridoma growth factor by human monocytes
26. Sandwich ELISA for detection of picogram quantities of interleukin-8
27. Differential local and systemic regulation of the murine chemokines KC and MIP2
28. In vivo dynamics of murine tumor necrosis factor-α gene expression: Kinetics of dexamethasone-induced suppression
29. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction [see comments]
30. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis
31. Role of tumor necrosis factor-α in lipopolysaccharide- induced pathologic alterations
32. Sepsis therapy trials: Continued disappointment or reason for hope?
33. Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome
34. Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor
35. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells
36. Recombinant interleukin 1 and tumor necrosis factor acting in synergy to release thromboxane, 6-KETO-PGF1 α and PGE2 by human neutrophils
37. Synergistic and overlapping activities of tumor necrosis factor-α and IL-1
38. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity
39. Destruction of rat islet cell monolayers by cytokines: Synergistic interactions of interferon-γ, tumor necrosis factor, lymphotoxin, and interleukin 1
40. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor: Synergistic action of the cytokines in the induction of inflammation and microvascular injury
41. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: Evidence for synergistic interactions between cytokines in vivo
42. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption
43. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat: A synergistic effect with interleukin 1
44. Synergism between IL-1β and TNF-α on the activity of the pituitary-adrenal axis and on food intake of rats
45. Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
46. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice
47. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial; The IL-1RA Sepsis Syndrome Study Group [see comments]
48. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis; The CB0006 Sepsis Syndrome Study Group
49. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection
50. Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals